NCT01262976View on ClinicalTrials.gov

Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults

PHASE2CompletedINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

January 17, 2011

Primary Completion Date

July 17, 2012

Study Completion Date

June 4, 2015

Conditions

Tuberculosis

Interventions

BIOLOGICAL

GSK's investigational vaccine 692342

Intramuscular, 2 doses

BIOLOGICAL

Physiological saline

Intramuscular, 2 doses

Trial Locations (1)

600113

GSK Investigational Site, Tharamani Chennai

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT01262976 - Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults | Biotech Hunter | Biotech Hunter